Locoregional Therapy for Intrahepatic Cholangiocarcinoma

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2023 May 16

PMID 37190311

Authors

Mackenzie Owen

Mina S Makary

Eliza W Beal

Affiliations

Soon will be listed here.

Abstract

Intrahepatic cholangiocarcinoma (ICC) has a poor prognosis, and surgical resection (SR) offers the only potential for cure. Unfortunately, only a small proportion of patients are eligible for resection due to locally advanced or metastatic disease. Locoregional therapies (LRT) are often used in unresectable liver-only or liver-dominant ICC. This review explores the role of these therapies in the treatment of ICC, including radiofrequency ablation (RFA), microwave ablation (MWA), transarterial chemoembolization (TACE), transarterial radioembolization (TARE), external beam radiotherapy (EBRT), stereotactic body radiotherapy (SBRT), hepatic arterial infusion (HAI) of chemotherapy, irreversible electroporation (IE), and brachytherapy. A search of the current literature was performed to examine types of LRT currently used in the treatment of ICC. We examined patient selection, technique, and outcomes of each type. Overall, LRTs are well-tolerated in the treatment of ICC and are effective in improving overall survival (OS) in this patient population. Further studies are needed to reduce bias from heterogenous patient populations and small sample sizes, as well as to determine whether certain LRTs are superior to others and to examine optimal treatment selection.

Citing Articles

The Efficacy and Safety of Hepatic Artery Infusion Chemotherapy Combined with Lenvatinib and Programmed Death (PD)-1 Inhibitors for Unresectable Intrahepatic Cholangiocarcinoma: A Retrospective Study.

Cai Y, Wen W, Xia Y, Wan R Curr Oncol. 2025; 32(2).

PMID: 39996887 PMC: 11854701. DOI: 10.3390/curroncol32020087.

Effectiveness and safety of transarterial chemoembolization combined with PD-1 inhibitors and lenvatinib for unresectable intrahepatic cholangiocarcinoma.

Huang J, Hu D, Hong X, Zhou W, Shen J, Lv P Eur Radiol Exp. 2025; 9(1):21.

PMID: 39966235 PMC: 11836246. DOI: 10.1186/s41747-025-00563-4.

Precision oncology: The role of minimally-invasive ablation therapy in the management of solid organ tumors.

Fazlollahi F, Makary M World J Radiol. 2025; 17(1):98618.

PMID: 39876886 PMC: 11755905. DOI: 10.4329/wjr.v17.i1.98618.

Efficacy of microwave ablation for intrahepatic cholangiocarcinoma: a systematic review and meta-analysis.

Song M, Li J, Li Y, Zhang C, Sigdel M, Hou R Quant Imaging Med Surg. 2025; 15(1):760-769.

PMID: 39839012 PMC: 11744144. DOI: 10.21037/qims-24-607.

A case report: deep and durable response to low-dose lenvatinib and tislelizumab in an elderly patient with advanced intrahepatic cholangiocarcinoma.

Zhang P, Wang X, Li R, Li X, Cheng K, Cao D Front Pharmacol. 2024; 15:1447582.

PMID: 39391699 PMC: 11464426. DOI: 10.3389/fphar.2024.1447582.

References

Inaba Y, Arai Y, Yamaura H, Sato Y, Najima M, Aramaki T . Phase I/II study of hepatic arterial infusion chemotherapy with gemcitabine in patients with unresectable intrahepatic cholangiocarcinoma (JIVROSG-0301). Am J Clin Oncol. 2010; 34(1):58-62. DOI: 10.1097/COC.0b013e3181d2709a. View

Ahn D, Bekaii-Saab T . Biliary cancer: intrahepatic cholangiocarcinoma extrahepatic cholangiocarcinoma gallbladder cancers: classification and therapeutic implications. J Gastrointest Oncol. 2017; 8(2):293-301. PMC: 5401855. DOI: 10.21037/jgo.2016.10.01. View

Lee S, Ko H, Shin J, Kim J, Chu H . Combination of intraoperative radiofrequency ablation and surgical resection for treatment of cholangiocarcinoma: feasibility and long-term survival. Diagn Interv Radiol. 2020; 26(1):45-52. PMC: 7075581. DOI: 10.5152/dir.2019.18552. View

Wu Z, Zhang H, Yang N, Zhao W, Fu Y, Yang G . Postoperative adjuvant transcatheter arterial chemoembolisation improves survival of intrahepatic cholangiocarcinoma patients with poor prognostic factors: results of a large monocentric series. Eur J Surg Oncol. 2012; 38(7):602-10. DOI: 10.1016/j.ejso.2012.02.185. View

Apisarnthanarax S, Barry A, Cao M, Czito B, DeMatteo R, Drinane M . External Beam Radiation Therapy for Primary Liver Cancers: An ASTRO Clinical Practice Guideline. Pract Radiat Oncol. 2021; 12(1):28-51. DOI: 10.1016/j.prro.2021.09.004. View

Shaker T, Chung C, Varma M, Doherty M, Wolf A, Chung M . Is there a role for Ytrrium-90 in the treatment of unresectable and metastatic intrahepatic cholangiocarcinoma?. Am J Surg. 2018; 215(3):467-470. DOI: 10.1016/j.amjsurg.2017.11.022. View

Eisele R, Chopra S, Glanemann M, Gebauer B . Risk of local failure after ultrasound guided irreversible electroporation of malignant liver tumors. Interv Med Appl Sci. 2015; 6(4):147-53. PMC: 4274353. DOI: 10.1556/IMAS.6.2014.4.2. View

Lee J, Yoon W, Koom W, Rim C . Efficacy of stereotactic body radiotherapy for unresectable or recurrent cholangiocarcinoma: a meta-analysis and systematic review. Strahlenther Onkol. 2018; 195(2):93-102. DOI: 10.1007/s00066-018-1367-2. View

Tao R, Krishnan S, Bhosale P, Javle M, Aloia T, Shroff R . Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients With Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis. J Clin Oncol. 2015; 34(3):219-26. PMC: 4980564. DOI: 10.1200/JCO.2015.61.3778. View

10.

Higaki T, Aramaki O, Moriguchi M, Nakayama H, Midorikawa Y, Takayama T . Arterial infusion of cisplatin plus S-1 against unresectable intrahepatic cholangiocarcinoma. Biosci Trends. 2018; 12(1):73-78. DOI: 10.5582/bst.2017.01320. View

11.

Boehm L, Jayakrishnan T, Miura J, Zacharias A, Johnston F, Turaga K . Comparative effectiveness of hepatic artery based therapies for unresectable intrahepatic cholangiocarcinoma. J Surg Oncol. 2014; 111(2):213-20. DOI: 10.1002/jso.23781. View

12.

Weiner A, Olsen J, Ma D, Dyk P, DeWees T, Myerson R . Stereotactic body radiotherapy for primary hepatic malignancies - Report of a phase I/II institutional study. Radiother Oncol. 2016; 121(1):79-85. PMC: 5543719. DOI: 10.1016/j.radonc.2016.07.020. View

13.

Kieszko D, Cisek P, Kordzinska-Cisek I, Grzybowska-Szatkowska L . Treatment of hepatic metastases with computed tomography-guided interstitial brachytherapy. Oncol Lett. 2018; 15(6):8717-8722. PMC: 6004646. DOI: 10.3892/ol.2018.8415. View

14.

Cercek A, Boerner T, Tan B, Chou J, Gonen M, Boucher T . Assessment of Hepatic Arterial Infusion of Floxuridine in Combination With Systemic Gemcitabine and Oxaliplatin in Patients With Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2019; 6(1):60-67. PMC: 6824231. DOI: 10.1001/jamaoncol.2019.3718. View

15.

Haidu M, Dobrozemsky G, Schullian P, Widmann G, Klaus A, Weiss H . Stereotactic radiofrequency ablation of unresectable intrahepatic cholangiocarcinomas: a retrospective study. Cardiovasc Intervent Radiol. 2011; 35(5):1074-82. DOI: 10.1007/s00270-011-0288-6. View

16.

Akinwande O, Shah V, Mills A, Noda C, Weiner E, Foltz G . Chemoembolization versus radioembolization for the treatment of unresectable intrahepatic cholangiocarcinoma in a single institution image-based efficacy and comparative toxicity. Hepat Oncol. 2018; 4(3):75-81. PMC: 6095156. DOI: 10.2217/hep-2017-0005. View

17.

Yang H, Cheng Z, Han Z, Liu F, Yu X, Yu J . Assessment of the Outcomes of Intrahepatic Cholangiocarcinoma After Ultrasound-Guided Percutaneous Microwave Ablation Based on Albumin-Bilirubin Grade. Cardiovasc Intervent Radiol. 2020; 44(2):261-270. DOI: 10.1007/s00270-020-02637-9. View

18.

Hu Y, Hao M, Chen Q, Chen Z, Lin H . Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma. Am J Transl Res. 2020; 12(10):6584-6598. PMC: 7653562. View

19.

Hammad A, Berger N, Eastwood D, Tsai S, Turaga K, Christian K . Is Radiotherapy Warranted Following Intrahepatic Cholangiocarcinoma Resection? The Impact of Surgical Margins and Lymph Node Status on Survival. Ann Surg Oncol. 2016; 23(Suppl 5):912-920. DOI: 10.1245/s10434-016-5560-1. View

20.

Owen M, Beal E . Minimally Invasive Surgery for Intrahepatic Cholangiocarcinoma: Patient Selection and Special Considerations. Hepat Med. 2022; 13:137-143. PMC: 8866996. DOI: 10.2147/HMER.S319027. View